

**REMARKS**


Claims 1- 13 are presently in the application. Claims 6-8 have been cancelled. Each of the remaining claims 1-5 and 9-13 has been either amended or renumbered. New claims 14, 15, 16 and 17 have been added. No additional claim fees are due.

Claim 1 has been amended to provide that the transgenic mouse exhibits a phenotype that models schizophrenia. Support is found in paragraph [0065], lines 2-3. Claims 2, 3 and 5 have been amended to delete preferred limitations, which have been separately included in new claims 15, 16 and 17. Claim 4 has been amended to correct antecedent basis and punctuation. The second claim numbered as claim 4 and claims 5 and 9-12 have been renumbered and amended to correct claim dependency. New claim 14 attributes the modeled schizophrenic phenotype to a mutation only of the endogenous *Npas3* gene.

No new matter has been added. Applicants respectfully request that Claims 1-5 and 9-17 be examined in this application.

Respectfully submitted,  
For: E. W. BRUNSKILL et al.

By:

  
\_\_\_\_\_  
Daniel F. Nesbitt  
Attorney for Applicants  
Registration No. 33,746  
(513) 229-0383  
Customer Number 38155

February 13, 2006  
Express Mail No. EV 734773944 US